When was Helex founded?

Helex was founded in 2021 and raised its 1st funding round within a year of its incorporation.

Where is Helex located?

Helex is headquartered in New York City, United States.

Who is the current CEO of Helex?

Poulami Chaudhuri of Helex. They have also founded 1 company.

How many employees does Helex have?

As of May 31, 2026, the latest employee count at Helex is 33.

Is Helex a funded company?

Helex is a funded company, having raised a total of $6M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Oct 02, 2021.

When was the latest funding round of Helex?

Helex's latest funding was a $***** Seed round on Oct 24, 2025, with participation from 3 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.12B in funding in 2026 to date.

Where does Helex rank among its competitors?

Helex ranks 67th amongst 900 active competitors, of which 299 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Helex, which secured $3.5M in Oct, 2025.

Who are the top competitors of Helex?

Helex's top competitors include Alnylam, Spark Therapeutics and Strand Therapeutics. Among them, Helex secured the most recent funding round in October, 2025.

Helex - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of next-generation gene-editing therapies. By using proprietary genomics data, bioinformatics, and intelligent data-driven platform the company has developed CRISPR-based genome editing therapeutics.

Website: www.helex.bio/
Email ID: *****@helex.bio

Key Metrics

Founded Year

2021

Location

New York City, United States

Stage

Seed

Total Funding

$6M in 2 rounds

Latest Funding Round

Seed, Oct 24, 2025, $*****

Investors

IndieBio & 3 more

Ranked

67^th among 900 active competitors

Employee Count

33 as on May 31, 2026

Similar Companies

Alnylam & 1051 more

View Helex's full profile

Helex is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
HELEX INC. CIN: 7008149 , United States, Active	Jun 13, 2023	-	-	-

Helex has raised a total funding of $6M over 2 rounds. Its first funding round was on Oct 02, 2021. Its latest funding round was a Seed round on Oct 24, 2025 for $*****. 3 investors participated in its latest round. Helex has 4 institutional investors.

Here is the list of recent funding rounds of Helex:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 24, 2025	6185713	Seed	2793091	7108801	6846321	7330432
Oct 02, 2021	5867408	Seed	7892868	6606043	IndieBio	8803452

Access funding benchmarks and valuations. Sign up today!

View details of Helex's funding rounds and investors

The founders of Helex are Rohini Kalvakuntla, Poulami Chaudhuri and Anirudh Nishtala. Poulami Chaudhuri is the CEO of Helex.

Here are the details of Helex's key team members:

Rohini Kalvakuntla: Co-Founder & CBO of Helex and founder of 2 other companies, RED and Empower Labs. They serve on the boards of 2 companies.
Contact Info: 1 email address and 1 phone number
Poulami Chaudhuri: Co-Founder & CEO of Helex.
Contact Info: 1 email address
Anirudh Nishtala: Co-Founder & COO of Helex.

View details of Helex's Founder profiles and Board Members

Helex's employee count trend

Helex has 33 employees as of May 26. Here is Helex's employee count trend over the years:

Uncover Helex's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Helex include Alnylam, Spark Therapeutics and Strand Therapeutics. Here is the list of Top 10 competitors of Helex, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Bellevue Healthcare Trust ... & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, MassChallenge & 19 others	70/100
4th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, RA Capital Management & 7 others	70/100
5th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
6th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Healthcap & 10 others	69/100
7th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
8th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	Fidelity Investments, T. Rowe Price & 9 others	69/100
9th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, EDBI & 16 others	68/100
10th	Liquidia 2004, Morrisville (United States), Public	Developer of therapeutics for pulmonary hypertension and cardiopulmonary conditions	$90.3M	Morningside, Gates & 18 others	68/100
67th	Helex 2021, New York City (United States), Seed	Provider of next-generation gene-editing therapies	$6M	Bluehill VC, SOSV & 2 others	59/100